Blackstone Inc. (NYSE:BX) is exploring a possible sale of ZO Skin Health, the medical-grade skincare company founded by dermatologist Dr. Zein Obagi. Reuters reported that the business could be valued at around $2 billion. The process is still in the early stages, and Blackstone is working with Citigroup and Raymond James on the potential sale. ZO sells products such as cleansers, serums, and exfoliators mainly through doctors and skincare professionals.
The timing could work in Blackstone Inc.’s favor. There has been growing interest from strategic buyers in skincare brands that have a clinical angle and are sold through physicians. These businesses can have an edge over regular over-the-counter skincare because customers tend to put more trust in products recommended by dermatologists and other professionals.
Blackstone Could Cash in on Rising Skincare Demand
A sale at around $2 billion would give Blackstone Inc. a meaningful opportunity to cash out of the investment and lock in the value it has created. It would also be a positive sign for the firm’s consumer healthcare and beauty strategy. Getting a strong exit in a market where buyers are still being selective would show that Blackstone can find good businesses, grow them, and eventually sell them at attractive valuations.ZO also has something that many skincare brands do not. Its products are sold through physicians and skincare professionals, which gives the brand a more clinical and premium image. That can help the company charge higher prices and keep customers coming back. It also makes ZO more interesting to larger beauty and healthcare companies that want to add a dermatologist-backed brand to their portfolio.
For Blackstone, selling ZO would also free up capital for other investments. The firm could return some of that money to its investors or put it into businesses where it sees more growth potential. For an asset manager of Blackstone’s size, being able to turn investments into cash is important because it helps support future fundraising and new deals.
The broader beauty market also shows that buyers are still prepared to spend heavily on brands they believe have strong growth potential. Reuters has pointed to deals such as L’Oréal’s $4.7 billion purchase of Kering’s beauty business and Henkel’s $1.4 billion acquisition of Olaplex as examples.
So, the main bullish argument is that Blackstone Inc. may have a good asset to sell at a time when strategic buyers are actively looking for premium, clinically positioned skincare brands. If multiple buyers come forward, Blackstone could have enough leverage to push the final price higher.
Potential Exit Comes with Meaningful Valuation Risks
The obvious problem is that the $2 billion valuation is only a reported target at this point. The sale process is still early, and there is no guarantee that Blackstone Inc. will actually get that price, or even complete a deal. Buyers could decide that ZO is not worth $2 billion and push for a lower valuation. If that happens, Blackstone would have to decide whether to accept a lower offer or simply keep the company and wait for a better opportunity.
There is also a case for Blackstone to hold on to ZO. The demand for dermatologist-backed and clinically focused skincare could continue to grow, giving the company more room to expand. ZO could potentially grow its international presence, reach more customers, or add new products over the next few years. Selling now means Blackstone could miss out on some of that upside.
Another issue is how many serious buyers actually emerge. Interest in the category does not automatically mean there will be several companies willing to pay a premium for ZO. If the buyer pool turns out to be small, Blackstone Inc.’s bargaining power could be weaker than expected. That could put pressure on the final sale price. And while a $2 billion valuation sounds attractive, the headline number alone does not tell us whether Blackstone would make a great return. That depends on what Blackstone originally paid for ZO, how much additional money it invested, and how long it has held the company. Without those details, it is difficult to judge the actual return.
Conclusion
The news is a positive development for Blackstone Inc., but there is still a lot that needs to happen before it becomes a real win for investors. ZO has several qualities that could attract strategic buyers, particularly its physician-led distribution, clinical reputation, and position in the premium skincare market. Those characteristics could help Blackstone command a strong price if several buyers compete for the business.
At the same time, the $2 billion figure should not be treated as a done deal. The process is still in its early stages, and Blackstone could end up selling for less, decide to hold the company, or fail to find a buyer at an acceptable price. For now, the story is more about the potential for a strong exit than a confirmed value creation event. The biggest upside would be a competitive bidding process that pushes the final price above $2 billion. The biggest risk would be weak buyer interest forcing Blackstone to either accept a discount or walk away from the sale.
READ NEXT: Chime Financial (CHYM) Moves Deeper into Banking with $590 Million Stride Acquisition and Smithfield Foods (SFD) Warns of Fresh Pork Loss as Industry Spreads Compress
This article is originally published at Insider Monkey.
Hedge Fund Resource Center